Abstract Number: 3096 • 2016 ACR/ARHP Annual Meeting
Association Between Smoking and Psoriatic Arthritis Among Psoriasis Patients and the General Population: Data from National Inpatient Sample
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis affecting approximately 520,000 patients in the US and up to one third of patients with psoriasis. Studies…Abstract Number: 1422 • 2016 ACR/ARHP Annual Meeting
Identifying Generic and Specific Patients’ Perspectives on Disease- and Treatment-Related Issues in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: A Qualitative Concept Mapping Study
Identifying generic and specific patients’ perspectives on disease- and treatment-related issues in rheumatoid arthritis, psoriatic arthritis, and psoriasis: a qualitative concept mapping studyT.S. Jørgensen1, L.…Abstract Number: 1668 • 2016 ACR/ARHP Annual Meeting
Selective Inhibition of Tumor Necrosis Factor-α Receptor 2 (TNFR2) Activity Alleviates Psoriasiform Inflammation in Mouse Models
Background/Purpose: Tumor necrosis factor-α (TNF) activates two receptors globally, TNFR1 and TNFR2. Neutralizing antibodies or soluble TNF receptors can inactivate TNF, blocking activity of both…Abstract Number: 1688 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity As Assessed By Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…Abstract Number: 1704 • 2016 ACR/ARHP Annual Meeting
Consistent Safety and Tolerability of Secukinumab over Long-Term Exposure in Patients with Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Background/Purpose: Pooled safety data from the psoriasis (PsO) and psoriatic arthritis (PsA) clinical trial programs of secukinumab (SEC), through approximately 1 year, have been reported…Abstract Number: 1705 • 2016 ACR/ARHP Annual Meeting
The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis
Background/Purpose: While rheumatoid arthritis (RA) has been linked to an increased incidence of osteoporosis (OP) and fracture, few studies have examined the risk of fracture…Abstract Number: 1714 • 2016 ACR/ARHP Annual Meeting
Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (PsO) are at increased risk of cardiovascular diseases (CVD) and the risk is higher in patients with…Abstract Number: 1719 • 2016 ACR/ARHP Annual Meeting
Secular Trends in Treatment Patterns for Psoriasis and Psoriatic Arthritis: A Population-Based Cohort Study
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are complex, multi-system diseases for which an ever-increasing landscape of therapies exists. Little is known about the population…Abstract Number: 1726 • 2016 ACR/ARHP Annual Meeting
An Integrated Safety Data Analysis Across All Phase II and Phase III Clinical Programs for Ustekinumab in Psoriatic Arthritis, Crohn’s Disease, and Psoriasis
Background/Objective:Therapeutic decisions are based on efficacy, but clinicians need to consider medication safety in this process. Here, we report ustekinumab (UST) integrated safety data in…Abstract Number: 1733 • 2016 ACR/ARHP Annual Meeting
Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis
Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…Abstract Number: 2170 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Risk in Patients with Psoriasis, Psoriatic and Rheumatoid Arthritis: A Prospective Study Using Secured Anonymised Information Technology Databank in Wales, United Kingdom
Background/Purpose: Compared with cardiovascular (CV) risk in rheumatoid arthritis (RA), precise CV risk in psoriatic arthritis (PsA) and psoriasis is less established, particularly the relative…Abstract Number: 2700 • 2016 ACR/ARHP Annual Meeting
The Lymphatic System: A Gatekeeper for Migration of Pathogenic T-Cells Towards Synovial Joints and Entheses in Psoriasis
Background/Purpose: Psoriasis (PsO) is a common inflammatory skin disease that is characterized by acanthosis, impaired immune cell migration, and remodeling of the vascular and lymphatic…Abstract Number: 921 • 2016 ACR/ARHP Annual Meeting
The Anti-IL-17A Antibody Secukinumab (Cosentyx®, AIN457) Diminishes the Expression of the NFκB Pathway Modulator Iκbζ
Background/Purpose: In order to better understand the IL-17A signaling pathway we have analyzed the effects of IL-17A in human primary synovial fibroblasts (SF), a…Abstract Number: 2721 • 2016 ACR/ARHP Annual Meeting
Impact of Nail Psoriasis on Clinical Presentation of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Studies have shown that psoriasis of the skin, scalp and/or nails precedes the appearance of psoriatic arthritis (PsA) by up to 12 years1,2; however,…Abstract Number: 959 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
Background/Purpose: Ixekizumab (IXE) is an IgG4 monoclonal antibody that binds with high affinity and specificity to the proinflammatory cytokine IL-17A. In this phase 3 study…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- Next Page »